Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Industry Watch.
Press releases published on March 26, 2025
International Wound Journal Publishes Positive Phase 2 Interim Data on Cell-free Amniotic Fluid Injectable Biologic for the Treatment of Venous Leg Ulcers
GlobeNewswire
·
March 26, 2025
RESEARCH TRIANGLE PARK, N.C., March 26, 2025 (GLOBE NEWSWIRE) -- Merakris Therapeutics announced the publication of positive clinical trial results from the first part of its ongoing Phase 2, multicenter trial. This study evaluates its biological drug, MTX …
Zymeworks Announces Participation in Upcoming Investor Conferences
GlobeNewswire
·
March 26, 2025
VANCOUVER, British Columbia, March 26, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to- …
UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab)
GlobeNewswire
·
March 26, 2025
REYKJAVIK, Iceland, PISCATAWAY, N.J. and LONDON, March 26, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of biosimilar medicines for patients worldwide, Kashiv Biosciences LLC …
FDA Issues Nyxoah an Approvable Letter for its Genio® System
GlobeNewswire
·
March 26, 2025
INSIDE INFORMATION REGULATED INFORMATION FDA Issues Nyxoah an Approvable Letter for its Genio® System Mont-Saint-Guibert, Belgium – March 26, 2025, 8:00am CET / 3:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), that …
La FDA Délivre à Nyxoah une Lettre d'Approuvabilité pour son système Genio®
GlobeNewswire
·
March 26, 2025
INFORMATIONS PRIVILÉGIÉES INFORMATIONS RÉGLEMENTÉES La FDA Délivre à Nyxoah une Lettre d'Approuvabilité pour son Système Genio® Mont-Saint-Guibert, Belgique – 26 mars 2025, 8h00 CET / 3h00 ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (« Nyxoah » ou la …
Pleco Therapeutics Announces Positive Outcome of Pre-IND meeting with FDA for PTX-252 in Acute Myeloid Leukaemia
GlobeNewswire
·
March 26, 2025
NIJMEGEN, The Netherlands, March 26, 2025 (GLOBE NEWSWIRE) -- Pleco Therapeutics, a clinical-stage biopharmaceutical company developing novel therapies for difficult-to-treat cancers, announces a positive outcome from its Pre-Investigational New Drug (Pre- …
Applied Food Sciences Earns Sello Chakra Certification for Sustainable Guayusa Sourcing, Empowering Amazonian Communities
GlobeNewswire
·
March 26, 2025
Kerrville, Texas, March 26, 2025 (GLOBE NEWSWIRE) -- Applied Food Sciences (AFS) is proud to receive the Sello Chakra (Chakra Seal), a certification from the Amazonian Kichwa communities of Ecuador, in recognition of its integral role in sourcing raw …
ONWARD Medical Announces First-in-Human Use of ARC-IM Lumbar Lead Designed to Restore Standing, Stepping, and Lower Limb Mobility
GlobeNewswire
·
March 26, 2025
The ARC-IM Lumbar Lead is the second model in the ARC-IM Lead family to be used in a clinical feasibility study The Company is building a portfolio of purpose-designed leads to optimize delivery of ARC-IM Therapy at various locations along the spinal cord …
Press Release: Chlamydia vaccine candidate granted fast track designation by the US FDA
GlobeNewswire
·
March 26, 2025
Chlamydia vaccine candidate granted fast track designation by the US FDA Chlamydia infection can contribute to pelvic inflammatory diseases in women, which can lead to pregnancy complications or infertility A phase 1/2 clinical study evaluating the …
Communiqué de presse : La FDA des États-Unis accorde une procédure accélérée au candidat-vaccin contre les infections à Chlamydia
GlobeNewswire
·
March 26, 2025
La FDA des États-Unis accorde une procédure accélérée au candidat-vaccin contre les infections à Chlamydia Les infections à Chlamydia peuvent contribuer à l’apparition d’inflammations pelviennes chez la femme et être à l’origine d’infertilité ou de …
BioVersys Reports Corporate Highlights and Key Financials for the Full Year 2024
GlobeNewswire
·
March 26, 2025
BASEL, Switzerland, March 26, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR BV100: Positive Phase 2 VABP trial read-out with excellent safety and efficacy data Alpibectir: Phase 2a EBA trial delivered very strong proof of concept …
Humacyte, Inc. Announces Pricing of Public Offering of Common Stock
GlobeNewswire
·
March 26, 2025
DURHAM, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the pricing of an …